Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci

Bente Glintborg; Anne Gitte Loft; Emina Omerovic; Oliver Hendricks; Asta Linauskas; Jakob Espesen; Kamilla Danebod; Dorte Vendelbo Jensen; Henrik Nordin; Emil Barner Dalgaard; Stavros Chrysidis; Salome Kristensen; Johnny Lillelund Raun; Hanne Lindegaard; Natalia Manilo; Susanne Højmark Jakobsen; Inger Marie Jensen Hansen; Dorte Dalsgaard Pedersen; Inge Juul Sørensen; Lis Smedegaard Andersen; Jolanta Grydehøj; Frank Mehnert; Niels Steen Krogh; Merete Lund Hetland

doi:10.1136/annrheumdis-2018-214788

Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci

Bente Glintborg, Anne Gitte Loft, Emina Omerovic, Oliver Hendricks, Asta Linauskas, Jakob Espesen, Kamilla Danebod, Dorte Vendelbo Jensen, Henrik Nordin, Emil Barner Dalgaard, Stavros Chrysidis, Salome Kristensen, Johnny Lillelund Raun, Hanne Lindegaard, Natalia Manilo, Susanne Højmark Jakobsen, Inger Marie Jensen Hansen, Dorte Dalsgaard Pedersen, Inge Juul Sørensen, Lis Smedegaard AndersenJolanta Grydehøj, Frank Mehnert, Niels Steen Krogh, Merete Lund Hetland

Department for Rheumatology and Spine Diseases

Original language	English
Journal	Annals of the Rheumatic Diseases
Volume	79
Issue number	2
Pages (from-to)	e14
ISSN	0003-4967
DOIs	https://doi.org/10.1136/annrheumdis-2018-214788
Publication status	Published - 2020

Keywords

Antirheumatic Agents
Biosimilar Pharmaceuticals
Etanercept
Humans
Registries
Treatment Outcome

Access to Document

10.1136/annrheumdis-2018-214788

Cite this

Glintborg, B., Loft, A. G., Omerovic, E., Hendricks, O., Linauskas, A., Espesen, J., Danebod, K., Jensen, D. V., Nordin, H., Dalgaard, E. B., Chrysidis, S., Kristensen, S., Raun, J. L., Lindegaard, H., Manilo, N., Jakobsen, S. H., Hansen, I. M. J., Dalsgaard Pedersen, D., Sørensen, I. J., ... Hetland, M. L. (2020). Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci. Annals of the Rheumatic Diseases, 79(2), e14. https://doi.org/10.1136/annrheumdis-2018-214788

Glintborg, B, Loft, AG, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K , Jensen, DV, Nordin, H, Dalgaard, EB, Chrysidis, S, Kristensen, S, Raun, JL, Lindegaard, H, Manilo, N, Jakobsen, SH, Hansen, IMJ, Dalsgaard Pedersen, D, Sørensen, IJ, Andersen, LS, Grydehøj, J, Mehnert, F, Krogh, NS & Hetland, ML 2020, 'Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci', Annals of the Rheumatic Diseases, vol. 79, no. 2, pp. e14. https://doi.org/10.1136/annrheumdis-2018-214788

@article{3cb2f95a8ded4192a8b803fc101e8faf,

title = "Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci",

keywords = "Antirheumatic Agents, Biosimilar Pharmaceuticals, Etanercept, Humans, Registries, Treatment Outcome",

author = "Bente Glintborg and Loft, {Anne Gitte} and Emina Omerovic and Oliver Hendricks and Asta Linauskas and Jakob Espesen and Kamilla Danebod and Jensen, {Dorte Vendelbo} and Henrik Nordin and Dalgaard, {Emil Barner} and Stavros Chrysidis and Salome Kristensen and Raun, {Johnny Lillelund} and Hanne Lindegaard and Natalia Manilo and Jakobsen, {Susanne H{\o}jmark} and Hansen, {Inger Marie Jensen} and {Dalsgaard Pedersen}, Dorte and S{\o}rensen, {Inge Juul} and Andersen, {Lis Smedegaard} and Jolanta Grydeh{\o}j and Frank Mehnert and Krogh, {Niels Steen} and Hetland, {Merete Lund}",

note = "COPECARE",

year = "2020",

doi = "10.1136/annrheumdis-2018-214788",

language = "English",

volume = "79",

pages = "e14",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "B M J Group",

number = "2",

}

TY - JOUR

T1 - Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci

AU - Glintborg, Bente

AU - Loft, Anne Gitte

AU - Omerovic, Emina

AU - Hendricks, Oliver

AU - Linauskas, Asta

AU - Espesen, Jakob

AU - Danebod, Kamilla

AU - Jensen, Dorte Vendelbo

AU - Nordin, Henrik

AU - Dalgaard, Emil Barner

AU - Chrysidis, Stavros

AU - Kristensen, Salome

AU - Raun, Johnny Lillelund

AU - Lindegaard, Hanne

AU - Manilo, Natalia

AU - Jakobsen, Susanne Højmark

AU - Hansen, Inger Marie Jensen

AU - Dalsgaard Pedersen, Dorte

AU - Sørensen, Inge Juul

AU - Andersen, Lis Smedegaard

AU - Grydehøj, Jolanta

AU - Mehnert, Frank

AU - Krogh, Niels Steen

AU - Hetland, Merete Lund

N1 - COPECARE

PY - 2020

Y1 - 2020

KW - Antirheumatic Agents

KW - Biosimilar Pharmaceuticals

KW - Etanercept

KW - Humans

KW - Registries

KW - Treatment Outcome

U2 - 10.1136/annrheumdis-2018-214788

DO - 10.1136/annrheumdis-2018-214788

M3 - Letter

C2 - 30573653

SN - 0003-4967

VL - 79

SP - e14

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 2

ER -